Medline Inc (MDLN) Stock Analysis
Verdict: WATCH (do not buy)
Guidance-driven selloff creates a value entry, but heavy private equity exiting and high leverage suggest the floor is not yet confirmed.
Investment score: 58/100
Analysis as of
Is Medline Inc stock worth reviewing? The TradeMates thesis
The TradeMates model views MDLN as a 'fallen angel' with strong underlying revenue growth (11.4% YoY) currently overshadowed by a significant guidance cut and heavy institutional selling.
7-factor investment score
- Valuation: 60/100 (weight 20%)
- Financial Health: 45/100 (weight 15%)
- Technical Momentum: 35/100 (weight 15%)
- Earnings Quality: 70/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 50/100 (weight 15%)
Medline Inc opportunities and risks
What speaks for MDLN
- Deep Value Relative to History and DCF
What speaks against MDLN
- Margin Compression in Supply Chain Segment
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| MDLN | 29.1x | 1.0x | 14.7x | 24.0% | 3.3% | 5.1% |
| SOLV | 10.5x | 1.8x | 7.1x | 53.7% | 17.3% | -1.4% |
| COO | 63.0x | 3.4x | 19.4x | 64.4% | 5.6% | 3.9% |
| ALGN | 30.0x | 3.0x | 14.5x | 66.5% | 10.0% | 6.1% |
| LNTH | 24.1x | 4.3x | 14.2x | 60.5% | 18.0% | 5.6% |
| Peer median | 27.1x | 3.2x | 14.3x | 62.4% | 13.7% | 4.8% |
Frequently asked questions about Medline Inc (MDLN)
Is MDLN stock a good investment?
The TradeMates model rates Medline Inc as WATCH (do not buy) with an investment score of 58/100. The TradeMates model views MDLN as a 'fallen angel' with strong underlying revenue growth (11.4% YoY) currently overshadowed by a significant guidance cut and heavy institutional selling. This is algorithmic model output, not personal investment advice.
Is MDLN stock a buy?
The TradeMates model verdict for MDLN is WATCH (do not buy) with an investment score of 58/100. Treat this as a model signal to review, not a personal buy recommendation.